Biggest Pharma company by market capitalisation launches new acid reflux drug - 95 per cent healing in just 8 weeks!

New drug offers fast relief and long-lasting acid control

Sun Pharmaceutical Industries has launched Fexuprazan 40 mg tablets in India under the brand name FEXUCLUE®. This new drug is approved for treating adults with Erosive Esophagitis, a condition caused by acid reflux that damages the food pipe lining. FEXUCLUE® is part of a new group of medicines called potassium-competitive acid blockers (P-CABs).

Faster Action and Longer Relief
Fexuprazan offers a fast onset of action and strong acid control. It has the longest half-life of 9 hours among P-CABs, which means it works longer and helps relieve nighttime symptoms. It can be taken with or without food, making it more convenient for patients.

Positive Study Results in India
The drug was tested in a Phase 3 study on Indian adults. The study showed that more than 95 per cent of patients experienced healing of Erosive Esophagitis within 8 weeks. The drug was also found to be well tolerated among the participants, showing its potential as an effective treatment option.

Deal with Daewoong Pharma
Sun Pharma signed an agreement with Daewoong Pharmaceutical, South Korea, to manufacture and sell FEXUCLUE® in India. Under the agreement, Daewoong will receive upfront and milestone payments, along with royalties on sales.

About Sun Pharma
Sun Pharmaceutical Industries Limited is India’s largest pharmaceutical company and a global leader in specialty generics. The company sells its products in over 100 countries and has manufacturing facilities across six continents. Its product range covers prescription medicines, generics, and over-the-counter health products. Sun Pharma is known for its strong presence in dermatology, ophthalmology, and onco-dermatology.

Rising Need for Better Treatment
In India, GERD affects 7.6 to 30 per cent of people, and nearly 9 per cent of them have Erosive Esophagitis. Many patients still don’t find full relief with current treatments. Sun Pharma hopes FEXUCLUE® will offer better outcomes and improve patients’ quality of life.

Disclaimer: The article is for informational purposes only and not investment advice